The aim of the present study was to test a panel of established ovarian cancer cell lines for their response to MDM2-p53 antagonists, Nutlin-3 and RG7388, alone and in combination with cisplatin and examine the mechanistic basis of these responses in relation to the genotype and induced gene expression of the cells. Here, MDM2 is linked to ovarian carcinoma.